AbbVie gets FDA approval for antibiotic treatment Emblaveo

US FDA approves AbbVie-Pfizer's treatment for intra-abdominal infections
AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections, including those caused by drug-resistant bacteria.
AbbVie Gets FDA Approval for New Antibiotic in the Face of Rising Resistance
The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in partnership with Pfizer. AbbVie acquired its share of the asset as part of its $63 billion buyout of Allergan.
AbbVie scores FDA nod for Pfizer-partnered antibiotic Emblaveo
Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S.,
FDA approves AbbVie’s Emblaveo for intra-abdominal infections
AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in conjunction with metronidazole for people aged 18 and over with complicated intra-abdominal infections (cIAI) and limited treatment options.
FDA Approves Combination Antibiotic for Complicated Infections
Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.
AbbVie gets FDA approval for antibiotic treatment Emblaveo (update)
AbbVie (ABBV) said it has received FDA approval for the combination antibiotic treatment Emblaveo, which was co-developed with Pfizer (PFE). Read more here.
AbbVie Gets FDA Approval of Intravenous Antibiotic Emblaveo
AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options. The drug, which combines aztreonam and avibactam, was approved in combination with metronidazole.
AbbVie: FDA Approves Emblaveo - Metronidazole Combination For Complicated Intra-Abdominal Infections
AbbVie (ABBV) announced the U.S. Food and Drug Administration approval of Emblaveo (aztreonam and avibactam). This marks the first
pharmaphorum21h
FDA clears new antibiotic for superbug infections
AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...
FiercePharma7d
Pfizer's Braftovi combo on track for full approval in win for FDA's Project FrontRunner
Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in ...
U.S. FDA approves Supernus' drug-device combination for Parkinson's disease
The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...
MedCity News8d
Pfizer Drug Hits Goals of Colorectal Cancer Study, Clearing Way to Seek Full FDA Approval
A Pfizer drug recently awarded accelerated FDA approval in colorectal cancer now has additional data showing it met key goals in its pivotal study, results that could support an application ...
BridgeBio: Post Attruby Approval, Shares Don't Look Such Good Value - Rating Downgrade
BridgeBio could be an acquisition target, but current financial challenges and competition suggest a "Hold" rating until ...